Change In Management

Sudeep Pharma Limited, a leading manufacturer of excipients and specialty ingredients catering to the food, pharmaceutical, and nutrition industries, today, in its exchange filing, has said that,

Mr. John Garcia (Vice President – Sales & Supply Chain) of Sudeep Pharma USA Inc, designated as Senior Management Personnel (SMP), has tendered his resignation with effect from the close of business hours on 6th February, 2026.

The company further stated that Mr. Garcia has tendered his resignation to pursue new challenges and opportunities.

Refer to Sudeep Pharma share News for more information.

The Stock made a high of ₹624.85 and a low of ₹599.65 before it ended at ₹618.30 (UP more than 3%) on the NSE when the market closed.

LAST ARTICLE – keystone realtors latest news

19 November 2025

Sudeep Pharma Limited, a legacy of delivering high-quality ingredient solutions for the Pharmaceutical, food, and nutraceutical industries, plans to raise ₹895 Crore through an IPO.

[Fresh Issue ₹95 Cr + OFS ₹800 Cr]

Sudeep Pharma IPO price is ₹563 – ₹593 per share

Sudeep Pharma: History

The Company was originally incorporated as Sudeep Pharma Private Limited, a private limited company under the Companies Act, 1956, on December 21, 1989.

The Company was then converted into a public limited company under a special resolution passed by the shareholders on August 17, 2024. Its name was subsequently changed to Sudeep Pharma Limited, as per a fresh certificate of incorporation issued by the Registrar of Companies on 21 October 21 2024.

LAST ARTICLE – Excelsoft Technologies IPO Review

Sudeep Pharma: Business

Sudeep Pharma Ltd. is a technology-led manufacturer of excipients and specialty ingredients for the pharmaceutical, food & nutrition industries, and is dedicated to contributing to the global healthcare ecosystem.

The Company leverages in-house developed technologies for processes such as,

• Encapsulation,
• Granulation,
• Spray drying,
• Trituration,
• Liposomal preparations, and
• Blending.

As per the F&S Report, Sudeep is one of the largest producers of food-grade iron phosphate for clinical nutrition, infant nutrition, and the food & beverage sectors (in terms of production capacity), supported by 3 manufacturing facilities in Vadodara, Gujarat, India, with a combined annual capacity of 65,579 metric tons, as of December 31, 2024.

It is one of the pioneers in India to introduce a product range of liposomal ingredients for nutrient absorption and stability, as per the F&S Report.

It is the only company in India and one of nine companies globally with certification of suitability issued by the Council of Europe (CEP).

Market Presence

The Company has established a presence in both local and overseas markets, including key regions such as Africa, Europe, the Middle East, South America, the United States, and Asia-Pacific.

Client List

As of December 31, 2024, the company had served over 1,100 clients, including 14 global Fortune 500 companies and marquee names like Danone, Merck, Pfizer, and Intas Pharma.

ALSO READ – GST 2.0 reforms

Strategies Ahead

• Expand into high-growth businesses.
• Expand market reach through multiple growth initiatives.
• Develop customized solutions and enter into strategic partnerships to drive growth.
• Integrate newly acquired entities and continue evaluating inorganic growth opportunities.
• Enhance manufacturing capabilities.

Company Promoters

1. Sujit Jaysukh Bhayani,
2. Avani Sujit Bhayani,
3. Shanil Sujit Bhayani,
4. Riva Resources Private Limited,
5. Bhayani Family Trust.

Refer to Sudeep Pharma DRHP for more information.

IPO Details

IPO date: 21 – 25 Nov 2025

Minimum Amount: ₹14,825

Minimum Bid: 25 Shares

Face Value (FV): ₹1

Listing On = NSE, BSE

Book Running Lead Managers

ICICI Securities

IIFL Capital Services

Financial

CONCLUSION

FinBlab recommends ‘SUBSCRIBE‘ ratings (keeping long-term view in mind) on Sudeep Pharma IPO

Do come back to know more about “upcoming ipos“

Disclaimer: The contents and data presented here are just for your information & personal use only. While much effort is made to provide the information, I (Vishal Dalwadi) or “FinBlab” do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.

The post Sudeep Pharma IPO – Review, Update appeared first on Upcoming ipos: Latest news on stocks, economy & finance.